Эфавиренз 600 мг таблетки, покрытые оболочкой

국가: 키르기스스탄

언어: 러시아어

출처: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

유효 성분:

Эфавиренз

제공처:

Strides Shasun Limited (Strides Shasun Limited)

ATC 코드:

J05AG03

INN (국제 이름):

Efavirenz

복용량:

600 мг

약제 형태:

таблетки, покрытые оболочкой

패키지 단위:

№30

처방전 유형:

по рецепту

Manufactured by:

Strides Shasun Limited (Индия)

치료 영역:

Противовирусное средство,для лечения ВИЧ инфекции

제품 요약:

ПЖВЛС: нет

승인 날짜:

2018-02-13

제품 특성 요약

YTBEP}I(NAIO
IIepnsrfi
Iena
o0ecIIerreHl{fl
Mulr
Av
# r .
IIHCTPYK\I4N
IIO
MEAIIIII,IHCKOMY
IIPI,IMEHEHIIIO
JIEKAPCTBEHHOIO
IIPEIIAPATA
SOABITPEH3
Topronoe
Ha3BaHrre:
3$anzpens
MeNqyHapoAHoe
HerrareuToBaHHoe
HarrMeHoBanrre:
3lpaeupens
JlercapcrnegHaff
Qopua:
ra6remlr,
noKpbrrbre
uneHo.rHoft
o6onoqKofi
Onracaune:
Ta6lerxu
KarlcynoBldgnofi
(popubr,
noKpbrrbre
rrJreHoqlloft
o6oloqxofi
6eroro
r{Jrr,r
fioqrr,r
6eloro rlBera,
fnaAKr,re
c o6erx
cropoH.
Cocran
Kaxgax
ra6nerxa,
[oKpbrrarr
nneno.rHoft
o6olo.moft
,
coAepxuT:
eKmu*Hozo
6eu4ecm6o:
e(panupeura
600
rrar
gcnoMozqmerbHue
6eu4ecm6a:
IIeJInTOJIO3a
MI,IKpOKpT{CTanrLrqecKar,
JIaKTO3a,
HaTpr{{
KpocKapMeJIJIo3a,
Harpl{s
nayp[ncynrQar,
rr4Apoxcr4npo[r{nrlennroJro3a,
BoAa
oqnqeHHar.
MarHr,rr
cTeapaT.
Ilneuoquoe
noKpwmue:
Universal:
HPMC
29l}lfunpoMeJlJro3a,
[oJrr.rsrr4JreHrJrr4KoJrb,
'rvrraHaAproKcr{.q
ElTl,xene3a
oKcr.rA
Nelrufi
8172,
)KeJre3a
oKcr,rA
rpacuufi
EI72
u xene3a
oKclrA
uepnufi
p]72.
(DapnrarcorepareBTuqecnaq
rpyurra:
flporunonupycHbre
rrperaparbr
AJrfl
cr,rcreMHofo
rIpI'IMeHeHI'Ia'
IIporHnoBI4pycHbIe
rlpelaparbr
rrprMoro
4eficrnur.
He"yuneosr.rAbr
-
unrn6uropu
o6paruofi
rpaHcKpunra3br.
3lpanupens.
Kor
ATX:
J05AG03
Oapuarco.ltorurrecKr.re
cnofi
crna
(DapnaxoduHaJvuKa
3(panvlpeus
npe4crarrxer
co6oft
ceJreKrr{BHrrft
ueHyx.ueognrulrfi
uuru6r.gop
o6paruoft
rpaHcKpl'Inmsu
(HHZOT)
nrzpyca
I4MMyHoAe(frEqzra
qeroBeKa
rrau
1
(BI4r{-1).
flsrye1;c;-
HeKoHKypeHTHbIM
Iauru6uropou
B?Ir{-1
o6pauroff
rpaHcKpr4rrr€t3br,
ne ranru6upyerBftIH-2
o6paruyro
rpaHcKpr{nra3y
}r
[HK-nonraMepa:]br
(o,
0,
T
u D) xneror
qeroBeKa.
9yncrnureJlbHocrb
BITITI
in
vitro:
musr4rrecKoe
3HarreHue
AaHHhrx
o
qyBcrBureJrbHocrr.r
BI4q-1
r<
e(panupeusy
in vitro
He
ycraHoBJreHo.
llporunonupycua-fl
e$$exrunuocrr
s(fannpeH3a
in
vitro
oIIeHI4Banacb
Ha Irlr]F.irrflx
nrau(po6nacrHbx
KJreroK,
MouoHyKJreapHbrx
KJreroK
uepzsepu.recroft
KpoBI''I
I'I KyJlbrypax
rraaxpo(paron/uoHoqrzron.
KoHrleurparlr{fl
s(faenpeusa,
neo6xo4nMaA
AJra
90-95% nnru6uponalr4fl
aranrl,IpoBaHHbrx
r
ra6oparopHbrM
ycnoBrr{M
rrrraMMoB
Arr